Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Immunicum AB (publ) to Present Preclinical Data on Ilixadencel's Mode of Action at the SITC Meeting in the US | |||
By: Nasdaq / GlobeNewswire - 21 Sep 2017 | Back to overview list |
||
Press Release21 September 2017 Immunicum AB (publ) to Present Preclinical Data on Ilixadencel's Mode of Action at the SITC Meeting in the USImmunicum AB (publ; First North Premier: IMMU.ST) a biopharmaceutical company advancing a novel immune-priming cancer treatment against a variety of solid tumors, today announced that the Society for Immunotherapy of Cancer (SITC) has accepted an abstract on ilixadencel's mode of action for a poster presentation at the SITC 32 nd Annual Meeting, held November 8-12, 2017 at the Gaylord National Hotel & Convention Center in National Harbor, Maryland. The poster titled "In vitro mode of action of ilixadencel - a cell-based allogeneic immune primer for intratumoral administration" will be presented by Immunicum's Chief Scientific Officer, Alex Karlsson-Parra. Immunicum will announce the complete data through a press release following the presentation. The date and time of the presentation will be available through the event section on Immunicum's website once public. For more information, please contact:
Carlos de Sousa, CEO, Immunicum
Investor relations, sweden
Helena Stångberg
Investor and Media Relations EU/US
MacDougall Biomedical Communications
The Company's Certified Adviser is Redeye AB
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Immunicum AB via GlobeNewswire
HUG#2135783
|
|||
|
|||
Copyright 2017 Nasdaq / GlobeNewswire | Back to overview list |